MIP Discovery
MIP Discovery is focused on tackling the opioid crisis sweeping north America. We are developing a suit of synthetic affinity reagents to enable next-gen mobile drug testing, starting with norfentanyl, the primary metabolite of fentanyl. MIP Discovery’s patented nanoMIP™ technology allows for the rapid development of polymer-based recognition reagents targeted to small molecules, viruses, or cell surface proteins. Rationally designed, and chemically manufactured, they are completely animal free, offer simplified logistics, and can be developed much more rapidly than biological alternatives, primarily antibodies. Alongside an advantageous supply chain, they also deliver on performance, continually demonstrating high specificity, sensitivity, and stability under extreme conditions. The business is also actively designing recognition reagents for cell & gene therapy enablement.
Product currently available for evaluation include norfentanyl nanoMIPs, COVID-19 nanoMIPs and Trypsin nanoMIPs.
Additional Info
We will be displaying a new product or promoting a new indication/enhanced feature for an existing product in our booth?
YesIncluded in the Export Interest Directory?
YesBusiness Needs:
Direct Sales, Distributor/Agent/Representative, InvestorProducts to be exported:
Norfentanyl nanoMIPs
COVID-19 nanoMIPs
Trypsin nanoMIPs